Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.
暂无分享,去创建一个
M. Cazzola | P. Rebulla | G. Barosi | F. Locatelli | E. Morra | S. Tura | S. Amadori | G. Visani | E. Alessandrino | M. Marchetti | A. Grossi | L. Liberato
[1] Nikolaos Laoutaris,et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients , 2002, British journal of haematology.
[2] R. Brand,et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. , 2002, Blood.
[3] J. Holland,et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] H. Deeg,et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. , 2002, Blood.
[5] A. Hagemeijer,et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. , 2001, Blood.
[6] L. Silverman. Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). , 2001, The oncologist.
[7] P. Venugopal,et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. , 2001, Blood.
[8] W. Hiddemann,et al. Phase II study of combination human recombinant GM‐CSF with intermediate‐dose cytarabine and mitoxantrone chemotherapy in patients with high‐risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): An Eastern Cooperative Oncology Group Study , 2001, American journal of hematology.
[9] G. Meloni,et al. Haematopoietic stem cell transplantation for patients with myelo‐dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) , 2000, British journal of haematology.
[10] G. Tjønnfjord,et al. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow , 2000, Bone Marrow Transplantation.
[11] Benz,et al. Low‐dose melphalan induces favourable responses in elderly patients with high‐risk myelodysplastic syndromes or secondary acute myeloid leukaemia , 2000, British journal of haematology.
[12] G Flandrin,et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] G Flandrin,et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] E. Solary,et al. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes , 1999, Leukemia.
[15] B. Djulbegovic,et al. The quality of medical evidence in hematology-oncology. , 1999, The American journal of medicine.
[16] M. Horowitz,et al. Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute lymphoblastic leukemia in first remission. , 1998, Leukemia research.
[17] D. Horsman,et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. , 1998, Blood.
[18] F. Appelbaum,et al. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. , 1998, Leukemia.
[19] Caillot,et al. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study , 1998, British journal of haematology.
[20] I. Dybedal,et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. , 1998, Blood.
[21] A. Gratwohl,et al. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey , 1998, Bone Marrow Transplantation.
[22] M. Labopin,et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome , 1998, Bone Marrow Transplantation.
[23] T. Okamoto. [Immunological abnormalities in myelodysplastic syndromes]. , 1998, Ryoikibetsu shokogun shirizu.
[24] G. Aprili,et al. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. , 1998, Haematologica.
[25] C. Wolf,et al. Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor‐α concentration , 1997 .
[26] M. Labopin,et al. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS , 1997 .
[27] A. List,et al. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. , 1997, Blood.
[28] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[29] P. Thall,et al. Allogeneic blood stem cell transplantation in advanced hematologic cancers , 1997, Bone Marrow Transplantation.
[30] M. Labopin,et al. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. , 1997, Blood.
[31] C. Bloomfield,et al. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] H. Hasle,et al. Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia. , 1996, Leukemia.
[33] F. Jensen,et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload , 1996, British journal of haematology.
[34] Hamblin Tj. Immunological abnormalities in myelodysplastic syndromes. , 1996 .
[35] K. Kojima,et al. Low-dose melphalan for treatment of high-risk myelodysplastic syndromes. , 1996, Leukemia.
[36] K. Sullivan,et al. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS‐related acute myeloid leukaemia , 1996, British journal of haematology.
[37] C. Chastang,et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Société Française de Greffe de Moelle. , 1996, Blood.
[38] S. Davies,et al. Unrelated donor bone marrow transplantation: influence of HLA A and B incompatibility on outcome. , 1995, Blood.
[39] T. Nakahata,et al. Effects of long-term treatment with recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome. , 1995, Leukemia & lymphoma.
[40] R. Morton,et al. Myelodysplastic syndrome treatment with danazol and cis‐retinoic acid , 1995, American journal of hematology.
[41] E. Hellström-Lindberg. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta‐analysis of 205 patients from 17 studies , 1995, British journal of haematology.
[42] E. Wattel,et al. Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases , 1994, British journal of haematology.
[43] Daniel S. Holland,et al. A review of 76 patients with myelodysplastic syndromes treated with danazol , 1994, Cancer.
[44] A. Ganser,et al. Effect of long-term treatment with recombinant human interleukin-3 in patients with myelodysplastic syndromes. , 1993, Leukemia.
[45] M. Dan,et al. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. , 1993, Blood.
[46] N. Gattermann,et al. Age‐related incidence and other epidemiological aspects of myelodysplastic syndromes , 1992, British journal of haematology.
[47] H. Gerhartz,et al. A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative Group. , 1992, Annals of hematology.
[48] R. Abels,et al. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. , 1991, Blood.
[49] A. Hoffbrand,et al. Long‐term trial with the oral iron chelator 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one (L1) I. IRON CHELATION AND METABOLIC STUDIES , 1990, British journal of haematology.
[50] J. Sklar,et al. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. , 1990, Blood.
[51] A. Gratwohl,et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG) , 1990, British journal of haematology.
[52] A. Avilés,et al. Randomized study of danazol vs. placebo in myelodysplastic syndromes. , 1989, Archivos de investigacion medica.
[53] R. Clark,et al. A randomized trial of 13‐cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome , 1987, British journal of haematology.
[54] R. Larson,et al. High‐dose cytosine arabinoside in the treatment of preleukemic disorders: A leukemia intergroup study , 1986, American journal of hematology.
[55] R H Brook,et al. A Method for the Detailed Assessment of the Appropriateness of Medical Technologies , 1986, International Journal of Technology Assessment in Health Care.
[56] David H. Gustafson,et al. Group Techniques for Program Planning: A Guide to Nominal Group and Delphi Processes , 1976 .